Metformin Use in Patients with Reduced Kidney Function

Introduction to Metformin Therapy

The American Journal of Kidney Diseases recommends that patients with one kidney can use metformin if their estimated glomerular filtration rate (eGFR) is ≥30 mL/min/1.73 m², with appropriate dose adjustments and monitoring 1, 2
The Kidney International guideline suggests that the decision to use metformin depends entirely on the patient's eGFR, not on whether they have one or two kidneys 1, 2

For patients with eGFR ≥45 mL/min/1.73 m², the Kidney International guideline recommends continuing standard metformin dosing (up to 2000-2550 mg daily) and monitoring eGFR at least annually 1, 2
For patients with eGFR 30-44 mL/min/1.73 m², the American Journal of Kidney Diseases guideline recommends reducing the metformin dose to a maximum of 1000 mg daily and monitoring eGFR every 3-6 months 1, 2
The American Journal of Kidney Diseases guideline also recommends considering additional dose reduction (to 500 mg daily) if comorbidities increase lactic acidosis risk (hypoperfusion, hypoxemia, liver disease) 1, 2

A Cochrane meta-analysis found zero cases of lactic acidosis in 20,000+ metformin patient-years and 55,451 non-metformin patient-years, demonstrating the low risk of lactic acidosis when metformin is used appropriately 5, 4
The American Journal of Kidney Diseases guideline recommends temporarily discontinuing metformin during acute illness or procedures that increase lactic acidosis risk, such as sepsis, hypoxia, shock, dehydration, and severe vomiting/diarrhea 4, 7, 8

The American Journal of Kidney Diseases guideline suggests that metformin use in chronic kidney disease (CKD) is associated with reduced mortality, which is critical for patient outcomes 6, 5, 4
The American Journal of Kidney Diseases guideline also recommends considering the cardiovascular benefits of metformin in overweight patients, providing strong rationale for continued use 6, 5

The Kidney International guideline recommends monitoring eGFR annually for patients with eGFR ≥60 mL/min/1.73 m², and every 3-6 months for patients with eGFR 45-59 mL/min/1.73 m² 1, 2
The American Journal of Kidney Diseases guideline recommends reducing the metformin dose to 1000 mg daily maximum and monitoring eGFR every 3-6 months for patients with eGFR 30-44 mL/min/1.73 m² 1, 2

The Kidney International guideline recommends not assuming that one kidney is a contraindication for metformin use, as the number of kidneys is irrelevant; only measured kidney function matters 1, 2
The American Journal of Kidney Diseases guideline recommends not using outdated creatinine cutoffs, but instead using eGFR, which is more accurate 3, 1
The American Journal of Kidney Diseases guideline also recommends not forgetting to counsel patients on "sick-day rules" to temporarily discontinue metformin during acute illness or procedures that increase lactic acidosis risk 4, 7, 8